EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudiePragmatische StudieOpen Access

4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications

Marlena Ornowska, Jessica Wittmann, Sandra Blitz, Hubert Wong, Gloria Vazquez-Grande, Anish R Mitra, Wesley Jang, Gordon Wood, Daniel Ovakim, David Forrest, Elizabeth Rohrs, Steven Reynolds

JAMA · 2026

DOI: 10.1001/jama.2026.6025 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA, 2026. Verfasst von Marlena Ornowska und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada. Hauptthemen laut MEDLINE: Catheter Obstruction, Catheter-Related Infections, Catheterization, Central Venous, Central Venous Catheters. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Use of central venous access devices (CVADs) can result in catheter-associated bloodstream infection, catheter occlusion, and catheter-related venous thrombosis. EDTA is a potent anticoagulant, antimicrobial, and antibiofilm agent that can be instilled into inactive CVAD ports as a locking fluid to decrease the risk of infection and maintain patency.

Objective

To determine whether a 4% tetrasodium EDTA (t-EDTA) locking fluid reduces CVAD-associated infections, occlusions, and thrombolytic use in adults treated in an intensive care unit (ICU). Design, Setting, and Participants Pragmatic, triple-blind, multicenter, cluster-randomized crossover trial including patients older than 18 years in the ICU with a CVAD in place and at least 1 lumen not in use. The trial was conducted in 6 Canadian hospitals (3 community hospitals and 3 academic centers). The first patient was enrolled on March 22, 2022, and the date of last follow-up occurred on September 25, 2024.

Interventions

The ICUs were randomized to use prefilled, identical, masked syringes containing 2.5 mL of t-EDTA (intervention) or control locking fluid (saline or 4% citrate for hemodialysis lines) for all trial participants over a 3.5-month period. After a 1-month follow-up period, ICUs crossed over to the opposing treatment group for another 3.5 months, with a subsequent 1-month follow-up. Main Outcomes and Measures The primary outcome was a composite incidence rate of CVAD-associated bloodstream infection, catheter occlusion requiring alteplase use, and/or catheter removal due to occlusion. Three of the 8 prespecified secondary outcomes included incidence rates of each component of the primary outcome separately.

Results

Of the 1574 eligible patients, 1468 (mean age, 60 [SD, 16.0] years; 37.7% female) were included in the analysis (696 receiving t-EDTA and 772 receiving control). The incidence rate of primary outcome events was 13.1 per 1000 catheter-days (74 events) in the t-EDTA group vs 19.9 per 1000 catheter-days (126 events) in the control group. In adjusted multivariate analysis, the incidence rate of the composite outcome was lower among patients receiving t-EDTA vs control (rate ratio, 0.68; 95% CI, 0.47-0.96; P = .03). Among the 3 components of the primary outcome, only the secondary outcome of CVAD occlusion requiring administration of alteplase significantly differed between the groups, with lower rates in the t-EDTA group vs control (66 vs 112; incidence rate, 11.67 and 17.73 per 1000 catheter-days, respectively; rate ratio, 0.66; 95% CI, 0.46-0.96). Conclusions and Relevance Compared with control locking solution, use of 4% t-EDTA locking solution for CVADs reduced the incidence of a composite outcome of CVAD-associated bloodstream infection, catheter occlusion requiring alteplase use, and catheter removal due to occlusion among adult patients in the ICU. Trial Registration ClinicalTrials.gov Identifier: NCT04548713

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Catheter ObstructionCatheter-Related InfectionsCatheterization, Central VenousCentral Venous CathetersEdetic AcidAgedFemaleHumansMaleMiddle AgedAnticoagulantsCross-Over StudiesFibrinolytic AgentsIntensive Care UnitsVenous ThrombosisAnti-Infective AgentsBiofilmsAdultIncidenceTreatment Outcome

Substanzen

AnticoagulantsEdetic AcidFibrinolytic AgentsAnti-Infective Agents

Autor:innen und Institutionen

  • Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada.
  • Department of Critical Care, Royal Columbian Hospital, New Westminster, British Columbia, Canada.
  • Fraser Health Authority, Surrey, British Columbia, Canada.
  • University of British Columbia Centre for Advancing Health Outcomes, Providence Healthcare, Vancouver, British Columbia, Canada.
  • School of Population and Public Health, University of British Columbia, Vancouver, Canada.
  • Section of Critical Care, University of Manitoba, Winnipeg, Canada.

Zitieren

APA

Ornowska, M., Wittmann, J., Blitz, S., Wong, H., Vazquez-Grande, G., Mitra, A. R., Jang, W., Wood, G., Ovakim, D., Forrest, D., Rohrs, E., & Reynolds, S. (2026). 4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications. JAMA. https://doi.org/10.1001/jama.2026.6025

Vancouver

Ornowska M, Wittmann J, Blitz S, Wong H, Vazquez-Grande G, Mitra AR, et al. 4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications. JAMA. 2026. doi:10.1001/jama.2026.6025

BibTeX
@article{Ornowska2026,
  author = {Ornowska, Marlena and Wittmann, Jessica and Blitz, Sandra and Wong, Hubert and Vazquez-Grande, Gloria and Mitra, Anish R and Jang, Wesley and Wood, Gordon and Ovakim, Daniel and Forrest, David and Rohrs, Elizabeth and Reynolds, Steven},
  title = {4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications},
  journal = {JAMA},
  year = {2026},
  doi = {10.1001/jama.2026.6025}
}
Kostenlos starten →